

# Frequently Asked Questions

## Introduction

This document attempts to answer the most common questions you are likely to have about the Award and the NeuroBlu platform. We plan to update this as needed when new questions arrive.

## General Sources of information

- For information on the NeuroBlu Award, please visit the Award home page at: <https://www.holmusk.com/news/neuroblu-award>
- For general information on the NeuroBlu product, please visit: <https://www.neuroblu.ai/>
- To learn more about Holmusk, visit the company web site at: <https://www.holmusk.com/>

## Unanswered questions

Please reach out to the NeuroBlu Award competition team in the first instance, via [info@neuroblu.ai](mailto:info@neuroblu.ai) (Please include "NeuroBlu Award" in your subject line – this will help us to route your message for immediate attention). We will attempt to respond as quickly as possible.

## NeuroBlu platform

### What is NeuroBlu?

NeuroBlu is our real-world data platform for mental and behavioural health. It gives you secure access to a unique, rich data set, plus the analytical tools and computing power you need to investigate your research question. (We use "behavioural health disorders" as a broad term encompassing mental health, psychiatry, and substance use-related disorders).

### What's special about the NeuroBlu data set?

- Its **size**: >50,000,000 rows of data from >560,000 patients
- **Longitudinal data**: over 20 years of data
- **Quantitative measures** including CGI-S
- **Medication data**
- **Natural Language Processing** extracts structured information from unstructured clinician notes

## What information is available in NeuroBlu?

Data includes:

- Patient demographics and geographical information
- Information on clinic appointments and hospitalisation
- Medication data
- Quantitative assessments including CGI-S
- Diagnostic codes
- Mental Status Examination (symptoms)\*
- Side effect data\*
- External stressors\*
- Family History\*

\*From NLP

Please visit the [NeuroBlu website](#) or [enquire](#) for more details

## What diagnoses does the data set cover?

The most common diagnoses in the data set include:

- Schizophrenia
- Schizoaffective disorders
- Panic disorder
- Pervasive & developmental
- Behavioural with physiological
- Physiologically caused
- Conduct disorders
- Personality disorders
- Generalized anxiety disorder
- PTSD
- ADHD
- Adjustment disorders
- Bipolar disorder
- Major depressive disorder

## Where does the data come from?

The data was collected by >25 sites in the USA that use our MindLinc Electronic Health records software. The data is anonymised and has all appropriate consents in place to be shared through the platform.

## Will I need ethical approval to work with your data?

The data is already consented for use in research, so you will not normally need any additional ethical approvals to work with the data.

## What do I need to use NeuroBlu?

Technical requirements are modest, as all computations are performed on our servers. NeuroBlu requires a recent web browser. To do any serious work in the platform will require some knowledge of the R or Python languages.

## NeuroBlu Award competition

### What is the prize?

The prize consists of:

- 6 months free subscription to NeuroBlu
- Introductory training and technical support from our team
- A cash award to support your research (€ 3,000)

### Why are you running this competition?

We are keen to raise awareness of the new platform and what it can do; and to learn from users what features they need and what kinds of questions they are interested in exploring.

### What kind of entries are you looking for?

We are looking for applications that propose high-quality research projects, that are a good fit to the capabilities of the platform, and with the potential to benefit patients.

### How will the proposals be assessed?

All proposals will be assessed against the criteria by a panel of our mental health, data science and commercial experts. A shortlist of the best proposals will be drawn up and the shortlisted applicants will discuss their ideas with our team. The award will go to the proposal ranked highest by our panel.

### What assessment criteria will be used?

Proposals will be assessed against the following criteria:

1. The scientific and clinical quality of the proposed research plan
2. The suitability of the applicant (principal investigator) and their publication track record
3. The suitability of the proposed project to the NeuroBlu platform and data set
4. The potential for impact from the project (commercial impact, peer-reviewed publications, patient benefit etc.)

5. Ethical use of data and AI within the project, including ensuring that the work will not foster healthcare inequalities

In addition to meeting the eligibility criteria **Error! Reference source not found.**, applicants will have to achieve a minimum qualifying score in each of three categories: publication and impact plan, patient benefit and ethics, and suitability for NeuroBlu.

## Am I free to publish the results?

Yes, and in fact we would encourage you to do so.

## What about my commercial confidentiality?

The usage agreement between Holmusk and the winners covers all aspects of confidentiality and intellectual property relating to the use of the platform. Please also consult the [Terms of Participation](#) for more information about participation.